Related Experiment Video
Updated: Jan 8, 2026
Author Spotlight: Development and Evaluation of a Cationic Nanoemulsion-Encapsulated Retinoic Acid System for Mucosal Vaccination
Published on: February 23, 2024
Programmable Antigen-Specific Immunity via Self-Adjuvanting Nanovaccines Co-Delivering Immune Modulators
Keita Ito1, Yoshiyuki Manabe1,2, Shino Ohshima3
1Department of Chemistry, Graduate School of Science, The University of Osaka, 1-1 Machikaneyama, Toyonaka, Osaka, 560-0043, Japan.
Abstract:
Cancer peptide vaccines harness the host immune system to generate tumor-specific immune responses, offering potential for treating metastatic cancers and preventing recurrence. However, the limited immunogenicity of peptide antigens restricts their clinical efficacy, necessitating strategies to enhance their potency. One promising approach involves the conjugation of antigens with adjuvants to elicit antigen-specific immune responses, thereby creating self-adjuvanting vaccines. In this study, we developed an improved platform for such vaccines. Specifically, the antigenic CH401 peptide was conjugated with the adjuvant (Pam3CSK4) and formulated into cationic lipid nanoparticles (LNPs) smaller than 100 nm to facilitate uptake by immune cells, with supplemental adjuvants incorporated to modulate immune responses. Notably, the microflow device iLiNP enabled precise, size-controlled LNP formulation from various components, supporting the systematic evolution of the self-adjuvanting vaccine platform. These vaccine candidates demonstrated enhanced immunogenicity, enabling precise modulation of immune responses in an antigen-specific manner. Notably, these vaccines elicited potent immune responses in humanized mouse models. Overall, this strategy represents a next-generation self-adjuvanting vaccine platform, capable of both enhancing and fine-tuning antigen-specific immune responses, holding great promise for innovative vaccine development.
Insights
This study presents a novel self-adjuvanting cancer vaccine platform using peptide antigens conjugated with adjuvants in cationic lipid nanoparticles (LNPs). The enhanced vaccine formulation boosts immunogenicity and precisely modulates immune responses, showing promise for cancer treatment.
Area of Science:
- Vaccinology
- Immunology
- Nanotechnology
Background:
- Cancer peptide vaccines aim to stimulate host immunity against tumors but face challenges due to limited antigen immunogenicity.
- Enhancing peptide antigen potency is crucial for effective cancer vaccine development, particularly for metastatic disease and recurrence prevention.
- Self-adjuvanting vaccines, created by conjugating antigens with adjuvants, offer a promising strategy to overcome these limitations.
Purpose of the Study:
- To develop an improved self-adjuvanting vaccine platform by conjugating the antigenic CH401 peptide with the adjuvant Pam3CSK4.
- To formulate these conjugates into cationic lipid nanoparticles (LNPs) smaller than 100 nm for enhanced immune cell uptake.
- To investigate the potential of supplemental adjuvants for modulating immune responses within the LNP formulation.
Main Methods:
- Conjugation of the CH401 peptide antigen with the Pam3CSK4 adjuvant.
- Formulation of antigen-adjuvant conjugates into cationic lipid nanoparticles (LNPs) using a microflow device (iLiNP) for precise size control (<100 nm).
- Incorporation of supplemental adjuvants to modulate immune responses.
- Evaluation of vaccine immunogenicity and immune response modulation in humanized mouse models.
Main Results:
- The developed vaccine candidates demonstrated significantly enhanced immunogenicity compared to conventional approaches.
- The platform enabled precise, antigen-specific modulation of immune responses.
- The cationic lipid nanoparticles facilitated efficient uptake by immune cells.
- Potent immune responses were successfully elicited in humanized mouse models.
Conclusions:
- This strategy represents a next-generation self-adjuvanting vaccine platform.
- The platform effectively enhances and fine-tunes antigen-specific immune responses.
- This innovative approach holds significant promise for the development of advanced cancer vaccines.
More Related Videos
07:32Evaluating the Immune Response of a Nanoemulsion Adjuvant Vaccine Against Methicillin-Resistant Staphylococcus aureus MRSA Infection
Published on: September 1, 2023
11:07Whole-animal Imaging and Flow Cytometric Techniques for Analysis of Antigen-specific CD8+ T Cell Responses after Nanoparticle Vaccination
Published on: April 29, 2015
Related Concept Videos
01:51Vaccinations
01:26Antigens Involved in Adaptive Immunity
Complete Antigens
Complete antigens possess both immunogenicity and...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:20Special Features of Adaptive Immunity
The primary cell types involved in adaptive immunity are T cells and B cells. Each type has a unique role in defending the body against pathogens. T cells are responsible for cell-mediated immunity. They identify and eliminate infected cells directly,...
01:27Tumor Immunotherapy
01:29Immune Response Against Viral Pathogens
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...